According to J.P. Morgan, Ariad Pharmaceuticals ARIA Overweight rating is maintained.
J.P. Morgan said that it is attending the 2011 ASH conference in San Diego, where interim data were presented on Sunday afternoon for the pivotal PACE trial evaluating ponatinib in chronic myeloid leukemia (CML) patients. “The bottom line is that so far PACE looks as if it is on track to be a successful trial with trends reminiscent of the Ph1 data. Reiterate OW.”
Ariad Pharmaceuticals closed on Friday at $11.63.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in